Design Therapeutics, Inc. is a biopharmaceutical company developing treatments for genetic diseases caused by nucleotide repeat expansions. Its portfolio includes products for Friedreich Ataxia and Myotonic Dystrophy Type-1, as well as other nucleotide repeat expansion-driven monogenic diseases like Huntington disease, among others. The company was founded in 2017 and is based in Carlsbad, California.